Vol. 2 No. 9 (2022)
Health Technology Reviews

Real-Time Continuous Glucose Monitoring for People Living With Type 2 Diabetes

Published September 26, 2022

Key Messages

  • The evidence regarding clinical and cost-effectiveness of real-time continuous glucose monitoring (rtCGM) compared to self-monitoring of blood glucose (SMBG) in patients with type 2 diabetes mellitus is summarized in this report.
  • Results from 5 systematic reviews and 1 randomized controlled study suggest that in adult patients, rtCGM may be favoured over SMBG in improving glycated hemoglobin levels, and in lowering time with extreme low or high blood glucose levels. However, the evidence is uncertain due to limited quality evidence.
  • In adults, limited safety evidence suggests that rtCGM is safe with low rates of adverse events.
  • A cost-effectiveness analysis conducted in Spain found that rtCGM is not a cost-effective option compared to SMBG in adults with type 2 diabetes mellitus.
  • No evidence was identified regarding clinical or cost-effectiveness of rtCGM in pediatric patients with type 2 diabetes mellitus.